27th-28th November | London
The Life Science IP conference will help to:
- Evaluate your current approach to life sciences patent eligibility - Refresh your understanding and gain insight into the new challenges in sessions led by the EPO, Novartis and Bracco
- Discover the variety of ways in which to monetise an IP portfolio with briefings from Strkyer, Harbour Litigation Funding and Ocean Tomo
- Assess logical, flexible IP strategies to help you avoid potential pitfalls with Esteve, and Tigenix
- Identify the best ways to protect patents, and how infringement proceedings are decided, hearing directly from the The Honourable Sir Richard Arnold of the UK High Court Presiding Judge Dr Mathias Zigann from Regional Munich Court
- Grasp the reality of patent innovation, and how to deliver on patient value with a gripping keynote given by UCB
- Involve yourself in the debate through a whole host of interactive sessions, panel debates, deep-dive workshops, and innovative networking opportunities
>> If you would like to receive the agenda in your inbox please contact email@example.com
Savvy IP protection is critical to enforce and defend IP rights, in addition to building a strong business model for future success. Successfully managed IP strategies will enable increased collaboration and massive innovation, driving forward the industry as a whole and providing a major tangible asset for life science businesses.
In this article, Legal IQ spoke exclusively to Ryan Zurek, Managing Director, Ocean Tomo, LLC about the best tactics for valuing life sciences patents, which life science areas are leading the way in IP monetisation and the metrics to consider when using IP to further profit for your business.
IP protection and enforcement is critical to securing business success and there are few industries where the impact of IP management is as dramatic as life science. Ahead of the Life Science IP 2018 Conference, we have put together this useful industry map which provides a high level overview of the latest industry developments affecting Life Science Intellectual Property in various European nations.
Early Certainty Programmes are designed to provide the patent application process with greater certainty and timeliness; we wanted to better understand the implications of this new time frame for in-house patent filing preparation.
Legal IQ sat down with Dieter Tzschoppe, Director in Operations Biotechnology Pure and Applied Organic Chemistry at the European Patent Office in order to discuss the Early Certainty Programme in more detail, and understand the impact it will have on life science companies.
The Innovation - Technology and Intellectual Property reports contains numerous market studies and features on best practices for day-to-day business, with exclusive rankings of top law firms and corporate companies, interviews with opinion makers and round-ups of the year. It also has company directories with detailed company profiles. Use these tools for competitive branding and position your company as one of the best international specialists among your clients and business partners.